Bristol Drops Virology Discovery In Latest R&D Reshuffling
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans to expand presence in Boston and San Francisco, while shuttering or de-emphasizing other locations, and to end virology discovery, in line with R&D strategy introduced in 2013.
You may also be interested in...
Bristol Advancing Two New Mechanisms In HIV, With Focus On Treatment-Experienced Patients
An attachment inhibitor entering Phase III may offer a new option for patients who have outlived the utility of other antiretrovirals. Bristol also is advancing a second-generation maturation inhibitor of HIV into Phase IIb studies, hoping to succeed where other candidates failed to address viral mutation.
Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.